Amgen Inc.

Specialty biologics for chronic conditions generate repeat prescriptions with relatively high continuation rates; management provided FY2026 revenue guidance of $37.0-$38.4B, reflecting meaningful forward visibility. However, Enbrel revenue fell approximately 33% in FY2025 due to Medicare redesign, illustrating the abrupt step-down risk embedded in this portfolio when policy changes strike blockbuster products.

Amgen reported 14 products with over $1 billion in annual sales for FY2025, with General Medicine (>$11B), Oncology (~$10B), Inflammation (>$7B), and Rare Disease (>$5B) each contributing materially. No single product represents more than roughly 8-9% of total revenue, though simultaneous biosimilar and Medicare pricing pressures across multiple products compress the practical diversification benefit.

Approximately 71% of FY2024 revenues came from the United States, with the remainder from international markets. This home-country concentration amplifies exposure to US reimbursement policy shifts, including Medicare price negotiation under the IRA, which is directly affecting multiple products simultaneously.

Non-GAAP operating margin is guided at approximately 45-46% of product sales for FY2026, reflecting meaningful fixed-cost leverage on Amgen's biologics manufacturing infrastructure. R&D investment is rising substantially, with FY2025 spending of $7.2B (up 22%), driven by the MariTide Phase 3 obesity program scaling into six concurrent global studies, which will pressure margins through the trial period.

Most of Amgen's product revenue comes from biologics treating chronic or serious conditions where patients typically remain on therapy for extended periods, providing repeat-purchase characteristics without formal contracts. Biosimilar revenues of approximately $3.7B in FY2024, which are commoditized and price-competitive by design, bring down the overall quality of the revenue mix.